Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
amyloid/cévní mozková příhoda
Odkaz je uložen do schránky
Strana 1 z 26 Výsledek
Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF THE INVENTION
The present invention relates to (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol
5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF THE INVENTION
The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising
4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2011/066343, filed Sep. 20, 2011, which claims priority from European Patent Application No. 10178315.7, filed Sep. 22, 2010 and European Patent Application No. 11157858.9, filed Mar. 11,
6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2012/053455, filed Feb. 29, 2012, which claims priority from European Patent Application No. 11156463.9, filed Mar. 1, 2011, the entire disclosures of which are hereby incorporated in their
Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase application, under 35 U.S.C. 371, of international application No. PCT/KR2009/007898, filed on Dec. 29, 2009, which claimed priority to Korean Patent Application No. 10-2008-0135519, filed on Dec. 29, 2008, the disclosures
Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2012/053863 filed Mar. 7, 2012, which claims priority from European Patent Application No. 11157418.2, filed Mar. 9, 2011, the entire disclosures of which are hereby incorporated in their
5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF THE INVENTION
The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions
4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS REFERENCE TO RELATED APPLICARIONS
This application is the national stage of PCT Application No. PCT/EP2014/062283, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171723.3,filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their
4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2014/062285, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171730.8, filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their
4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2014/062286, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171720.9, filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their
Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF THE INVENTION
The present invention belongs to the field of medical chemistry and relates to the compound of formula (I), a primary triclyclic amine, which inhibits the tPA-induced activation of the enzyme Erk 1/2 and is promising for, the treatment of neurodegenerative illnesses, such as,
Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
The present invention relates to novel tricyclic sulfonamide compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to
Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
The present invention relates to novel tricyclic sulfonamide compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to
2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national stage of PCT Application No. PCT/EP2015/079981, filed Dec. 16, 2015, which claims priority from European Patent Application No. 14198977.2, filed Dec. 18, 2014 and European Patent Application No. 15164704.7, filed Apr. 22,
Biphenyl hydroxy imino butyric acids and their derivatives for treating arthritis
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
The present invention relates to novel biphenyl butyric acid compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to
Nejúplnější databáze léčivých bylin podložená vědou
- Funguje v 55 jazycích
- Bylinné léky podporované vědou
- Rozpoznávání bylin podle obrázku
- Interaktivní mapa GPS - označte byliny na místě (již brzy)
- Přečtěte si vědecké publikace související s vaším hledáním
- Hledejte léčivé byliny podle jejich účinků
- Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty
Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu
